Eloxx Pharmaceuticals, Inc. (ELOX) News
Follow Eloxx Pharmaceuticals, Inc. (ELOX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
FDA Clears Eloxx's Exaluren for Phase 2 Trial
The FDA cleared Eloxx Pharmaceuticals' Exaluren for a Phase 2 trial in ADPKD.
REGULATION | Oct 29, 2026, 12:11 PM UTC
M
Lucid initiates ELOX at Buy with $38 target
Lucid initiates ELOX at Buy with a $38 price target; no further catalyst was supplied in the alert.
EQUITY | Aug 20, 2026, 12:50 PM UTC
L
Eloxx Pharmaceuticals Reports Q2 2026 Results
Eloxx Pharmaceuticals reports second quarter 2026 financial results and provides business update
EARNINGS | Aug 12, 2026, 10:01 AM UTC
L
ELOX Initiated Outperform W/$40.00 PT at LifeSci Capital
ELOX Initiated Outperform W/$40.00 PT at LifeSci Capital
EQUITY | Jul 22, 2026, 12:02 PM UTC
L
ELOX Initiated Buy W/$43.00 PT at Guggenheim
ELOX Initiated Buy W/$43.00 PT at Guggenheim
EQUITY | Jul 20, 2026, 11:49 AM UTC
L
ELOX new Buy W/ $43 PT @ GUGG
ELOX new Buy W/ $43 PT @ GUGG
EQUITY | Jul 20, 2026, 11:36 AM UTC
L
Eloxx Pharmaceuticals initiated with bullish view at Guggenheim
Eloxx Pharmaceuticals initiated with bullish view at Guggenheim
EQUITY | Jul 20, 2026, 12:44 AM UTC
L
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Can Fite Biopharma (AMEX: CANF ) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million. Regencell Bioscience (NASDAQ: RGC ) stock moved upwards by 35.79% t
EQUITY | Jul 01, 2026, 05:05 PM UTC